{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11(2)"],"submitter":["Zolk O"],"pubmed_abstract":["<h4>Background</h4>In childhood cancer survivors (survival of 5 years or more after diagnosis), cardiac toxicity is the most common nonmalignant cause of death attributed to treatment-related consequences. Identifying patients at risk of developing late cardiac toxicity is therefore crucial to improving treatment outcomes. The use of genetic markers has been proposed, together with clinical risk factors, to predict individual risk of cardiac toxicity from cancer therapies, such as doxorubicin.<h4>Objective</h4>The primary aim of this study is to evaluate the value of multimarker genetic testing for RARG rs2229774, UGT1A6 rs17863783, and SLC28A3 rs7853758 for predicting doxorubicin-induced cardiotoxicity. The secondary aim is to replicate previously described associations of candidate genet"],"journal":["JMIR research protocols"],"pagination":["e27898"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8895281"],"repository":["biostudies-literature"],"pubmed_title":["Cardiovascular Health Status And Genetic Risk In Survivors of Childhood Neuroblastoma and Nephroblastoma Treated With Doxorubicin: Protocol of the Pharmacogenetic Part of the LESS-Anthra Cross-Sectional Cohort Study."],"pmcid":["PMC8895281"],"pubmed_authors":["Zolk O","Spix C","Graf N","Abdul-Khaliq H","Gebauer J","von dem Knesebeck A","Abd El Rahman M","Mayer B","Langer T","Simon T","Hero B","Elsner S"],"additional_accession":[]},"is_claimable":false,"name":"Cardiovascular Health Status And Genetic Risk In Survivors of Childhood Neuroblastoma and Nephroblastoma Treated With Doxorubicin: Protocol of the Pharmacogenetic Part of the LESS-Anthra Cross-Sectional Cohort Study.","description":"<h4>Background</h4>In childhood cancer survivors (survival of 5 years or more after diagnosis), cardiac toxicity is the most common nonmalignant cause of death attributed to treatment-related consequences. Identifying patients at risk of developing late cardiac toxicity is therefore crucial to improving treatment outcomes. The use of genetic markers has been proposed, together with clinical risk factors, to predict individual risk of cardiac toxicity from cancer therapies, such as doxorubicin.<h4>Objective</h4>The primary aim of this study is to evaluate the value of multimarker genetic testing for RARG rs2229774, UGT1A6 rs17863783, and SLC28A3 rs7853758 for predicting doxorubicin-induced cardiotoxicity. The secondary aim is to replicate previously described associations of candidate genet","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Feb","modification":"2025-04-04T07:50:59.893Z","creation":"2025-04-04T07:50:59.893Z"},"accession":"S-EPMC8895281","cross_references":{"pubmed":["35175211"],"doi":["10.2196/27898"]}}